The Funded: Accel and three unicorns score jumbo deals at midweek
Antheia Inc., Menlo Park, $73 million: Viking Global Investors led the Series B funding of this company that’s making plant-based medicines using synthetic biology. Sherpalo Ventures and Eric Schmidt’s Hillspire…
Money on the Move: June 30 – July 6
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary active…
Startup using yeast to make drug components raises $73M
The idea: A California company producing active pharmaceutical ingredients with engineered yeast raised $73 million to bring its first product to market…
Top 10 Synthetic Biology Companies
Any doubts about synthetic biology’s attractiveness to investors were likely shattered during the first quarter, when investors pumped $4.6 billion into such companies—more than four times the $904.7 million invested…
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing. The oversubscribed round was led by Viking Global Investors and included…
Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary…
Say goodbye to plants: Synbio player Antheia earns new backers in quest to redesign flora-derived…
The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors view those cell engineering platforms…
Synthetic-Biology Startup Antheia Raises $73 Million
Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new venture-capital financing…
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia’s first pharmaceutical compounds to market, expand its pipeline and scale production in global markets…
Synthetic biology firm Antheia collects $73m Series B
Menlo Park, California-based Antheia, a synthetic biology company, has raised $73 million in Series B financing. Viking Global Investors led the round with participation from other investors that included Sherpalo Ventures and Hillspire…
